NasdaqGS - Nasdaq Real Time Price USD

Exelixis, Inc. (EXEL)

36.22

+0.48

+(1.34%)

As of 12:25:10 PM EDT. Market Open.

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks 4 days ago

EXEL
+1.34%
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 4 days ago

EXEL
+1.34%
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 7 days ago

EXEL
+1.34%
The Smartest Biotech Stocks to Buy With $50

Here are two great examples in the biotech industry: Viking Therapeutics (NASDAQ: VKTX) and Exelixis (NASDAQ: EXEL). Viking Therapeutics, a mid-cap biotech, is looking to make waves in the fast-growing market for weight management medicines. It will move forward with phase 3 studies for this product soon.

Motley Fool 12 days ago

EXEL
+1.34%
VKTX
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

CORT and AXSM are in the spotlight this week following the announcement of study data.

Zacks 12 days ago

CORT

EXEL
+1.34%
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is […]

Insider Monkey 13 days ago

EXEL
+1.34%
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.

Zacks 18 days ago

EXEL
+1.34%
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of unresectable, locally advanced or metastatic pancreatic neuroendocrine tumors and extra-pancreatic NET in patients ages 12 or older, Citi analyst David Lebowitz tells investors in a research note. The label expansion, which was based on progression-free survival results in the placebo-controlled Phase 3 CABINET trial, which showed a median increase in PFS ove

TipRanks 19 days ago

EXEL
+1.34%
Exelixis to present positive preclinical data across pipeline portfolio at AACR

The company states: “Exelixis (EXEL) announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research Annual Meeting 2025 taking place April 25-30 in Chicago, IL. Exelixis will present preclinical data for XL495 and XL309, small molecules that have demonstrated synthetic lethality in the context of certain genetic anomalies frequently found in some tumors. Preclinical data will also be presented for the PD-L1xNKG2A-targeting bispecific

TipRanks 19 days ago

EXEL
+1.34%
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.

Zacks 19 days ago

EXEL
+1.34%
Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

Exelixis (NasdaqGS:EXEL) saw an 11% share price increase over the last quarter, a period marked by significant achievements including the FDA's approval of CABOMETYX® for treating a broader range of pancreatic and extra-pancreatic neuroendocrine tumors. This regulatory milestone adds to its existing portfolio, potentially enhancing market confidence. During the same period, the company reported robust earnings growth and initiated a $500 million share repurchase program, reflecting a strong...

Simply Wall St. 19 days ago

EXEL
+1.34%
Here's Why Exelixis (EXEL) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 20 days ago

EXEL
+1.34%
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif., March 26, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET); and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or m

Business Wire 20 days ago

EXEL
+1.34%
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

ALAMEDA, Calif., March 25, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL.

Business Wire 20 days ago

EXEL
+1.34%
Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Biotech leader Exelixis stock is attempting to regain a recent buy point during Monday's stock market rally.

Investor's Business Daily 22 days ago

EXEL
+1.34%
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 25 days ago

EXAS
-0.99%
EXEL
+1.34%
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 26 days ago

EXEL
+1.34%
Exelixis Growth Continues with Big Money Boosts

Oncology company Exelixis, Inc. (EXEL) growing business, eyeing more.

FX Empire 27 days ago

EXEL
+1.34%
Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could […]

Insider Monkey 28 days ago

EXEL
+1.34%
Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

EXEL
+1.34%
AMGN

Performance Overview

Return	EXEL	S&P 500 (^GSPC)
YTD	+8.77%	-7.65%
1-Year	+59.56%	+7.31%
3-Year	+56.86%	+23.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Exelixis, Inc. (EXEL)

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

The Smartest Biotech Stocks to Buy With $50

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

Exelixis to present positive preclinical data across pipeline portfolio at AACR

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Exelixis Growth Continues with Big Money Boosts

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

Performance Overview